•
Dec 31, 2022

Baxter Q4 2022 Earnings Report

Reported an increase in fourth-quarter sales and provided an update on actions to improve operational efficiency.

Key Takeaways

Baxter International Inc. reported fourth-quarter sales of $3.9 billion, an 11% increase on a reported basis. U.S. GAAP diluted earnings per share (EPS) was $0.36, and adjusted diluted EPS was $0.88. The company is implementing a new operating model and planning a spinoff of Renal Care and Acute Therapies businesses.

Fourth-quarter sales increased 11% on a reported basis, 17% on a constant currency basis, and 2% on an operational basis.

U.S. sales increased 25% on a reported basis but declined 1% on an operational basis.

Net income attributable to Baxter was $181 million, or $0.36 per diluted share, on a U.S. GAAP basis.

Adjusted net income attributable to Baxter totaled $444 million, or $0.88 per diluted share.

Total Revenue
$3.89B
Previous year: $3.51B
+10.6%
EPS
$0.88
Previous year: $1.04
-15.4%
Gross Profit
$1.46B
Previous year: $1.41B
+4.1%
Cash and Equivalents
$1.72B
Previous year: $2.95B
-41.8%
Total Assets
$28.3B
Previous year: $33.5B
-15.6%

Baxter

Baxter

Baxter Revenue by Geographic Location

Forward Guidance

Baxter expects sales growth of 1% to 2% on a reported basis and flat to 1% on a constant currency basis for full-year 2023. The company expects U.S. GAAP earnings of $1.43 to $1.63 per diluted share and adjusted earnings of $2.75 to $2.95 per diluted share.

Positive Outlook

  • Sales growth of 1% to 2% on a reported basis is expected for full-year 2023.
  • U.S. GAAP earnings of $1.43 to $1.63 per diluted share are anticipated for full-year 2023.
  • Adjusted earnings of $2.75 to $2.95 per diluted share are projected for full-year 2023.
  • Savings programs are expected to ramp over the course of the year, with the majority of the benefit being realized in the second half of the year.
  • Impact from inflationary pressures on earnings is expected to begin to ease in the second half of the year.

Challenges Ahead

  • Challenging first half of 2023 is expected due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022.
  • Guidance for 2023 reflects incremental employee compensation costs.
  • Higher interest expense is expected to impact 2023 earnings.
  • An increased tax rate assumption compared to full-year 2022 is expected.
  • Sales are expected to decline approximately 3% on a reported basis and 1% on a constant currency basis for first-quarter 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income